Genome Analysis for Drug and Molecule Development

Genomics, particularly high-throughput sequencing and characterization of expressed human genes, has been used as a tool for accelerating drug development. Pharmacogenomics is the application of genomic technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on market.

Three genome analysis techniques, genome-wide association studies (GWAS), exome sequencing, and whole genome sequencing, are currently use in drug development. GWAS are mainly applied for advancing the understanding of the biological basis of common disorders such as cardiovascular disease, diabetes, infectious diseases, inflammatory and autoimmune disorders. Exome analysis is able to identify rare and common coding variants, which allows for the assessment of the likelihood of functional impact and predicted deleteriousness by various predictive metrics.. Whole genome sequencing is of particular interest for the study of rare genetic disorders on clinical grounds.

Figure 1. Schematic of genomic tools applied to antimicrobial-drug discovery (Moir, et al. 1999)

Transcriptional profiling of cells and tissues is perhaps the most common technologies, that is used in mapping responses to compounds, the interrogation of tissues and cells for the expression of a target of interest, assisting with the identification of causal variants associated with clinical phenotypes. Moreover, transcriptomics is also an important tool for the discovery of biomarkers for patient stratification in clinical trials.

Figure 2. Transcript profiling approach for understanding novel drug mechanisms (Bumol, et al. 2001)

CRISPR-based genome editing is adopted to create targeted genetic perturbations at scale and screen for a phenotype of interest. And CRISPR screens have quickly driven target prioritization in a variety of disease models and clarified the targets, enhancers, and resistance genes for existing drugs.

Creative BioMart Microbe offers innovative portfolios of high-throughput sequencing (HTS) systems and services for the drug development pipeline. Our services consist of:

• Whole-genome sequencing
• Whole-exome sequencing
• RNA sequencing
• Drug response RNA biomarker discovery
• Cancer sequencing
• High-throughput genotyping research
• Epigenetics
• Bioinformatics
• Custom service

Creative BioMart Microbe is a quality and compliance-driven global leader in Bio-Pharmaceutical Microbiology. Our laboratory professionals have extensive experience in performing genome analysis for drug and molecule development Please feel free to contact us for more information.

References:

1. Bumol, T. F., Watanabe, A. M. Genetic Information, Genomic Technologies, and the Future of Drug Discovery. JAMA. 2001, 285(5): 551.
2. Moir, D. T.; et al. Genomics and Antimicrobial Drug Discovery. Antimicrobial Agents and Chemotherapy. 1999, 43(3): 439-446.
3. Spreafico, R., et al. Advances in Genomics for Drug Development. Genes. 2020, 11(8): 942.